Literature DB >> 21319995

Association between single nucleotide polymorphisms in the cyclooxygenase-2, tumor necrosis factor-α, and vascular endothelial growth factor-A genes, and susceptibility to hepatocellular carcinoma.

Antonio Giacalone1, Giuseppe Montalto, Lydia Giannitrapani, Daniele Balasus, Angela Terranova, Melchiorre Cervello, Maurizio Soresi, Lorenzo Marasà.   

Abstract

Cyclooxygenase-2 (COX-2), vascular endothelial growth factor-A (VEGF-A), and tumor necrosis factor-α (TNF-α) are mediators of inflammation and angiogenesis; all of them are produced in liver cirrhosis (LC) and in hepatocellular carcinoma (HCC). It was proposed that there is an association between single nucleotide polymorphisms (SNPs) and HCC. These allelic variants influence the transcriptional activity of these genes, and therefore the proteins levels. The VEGF-A pathway is a potential therapeutic target in HCC, and several antiangiogenic agents have entered clinical trials in HCC. We evaluated the frequency of SNPs of COX-2, TNF-α, and VEGF-A genes in patients with HCC versus LC patients and a control group. The aim of this article was to verify the correlation between the allelic variations and the risk of developing HCC. The study included 96 HCC, 79 LC patients, and 162 healthy subjects. The evaluation of SNPs was performed by the restriction fragment length polymorphism (RFLP-PCR) method. The SNPs analyzed were: -1195 G>A of the COX-2 gene, -308 G>A of the TNF-α gene, and +936 C>T of the VEGF-A gene. Chi-square and Fisher exact tests were used for statistical analysis. Our results confirm that carriers with the C allele in the VEGF-A gene are more frequent in HCC versus LC (p=0.039), suggesting that this SNP may predispose to the development of HCC.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21319995     DOI: 10.1089/omi.2010.0095

Source DB:  PubMed          Journal:  OMICS        ISSN: 1536-2310


  11 in total

1.  Epidermal growth factor receptor pathway polymorphisms and the prognosis of hepatocellular carcinoma.

Authors:  Wenjia Wang; Xiao-Pin Ma; Zhuqing Shi; Pengyin Zhang; Dong-Lin Ding; Hui-Xing Huang; Hexi Ge Saiyin; Tao-Yang Chen; Pei-Xin Lu; Neng-Jin Wang; Hongjie Yu; Jielin Sun; S Lilly Zheng; Long Yu; Jianfeng Xu; De-Ke Jiang
Journal:  Am J Cancer Res       Date:  2014-12-15       Impact factor: 6.166

2.  The association between cyclooxygenase-2 1195 G/A polymorphism and hepatocellular carcinoma: evidence from a meta-analysis.

Authors:  Xianmin Bu; Chenghai Zhao
Journal:  Tumour Biol       Date:  2013-03-14

3.  HapMap-based study of CIP2A gene polymorphisms and HCC susceptibility.

Authors:  Yuchun Li; Kaijuan Wang; Liping Dai; Peng Wang; Chunhua Song; Jianxiang Shi; Pengfei Ren; Hua Ye; Jianying Zhang
Journal:  Oncol Lett       Date:  2012-05-23       Impact factor: 2.967

4.  Association of VEGFA polymorphisms with susceptibility and clinical outcome of hepatocellular carcinoma in a Chinese Han population.

Authors:  Fei Liu; Limei Luo; Yonggang Wei; Wentao Wang; Tianfu Wen; Jiayin Yang; Mingqing Xu; Bo Li
Journal:  Oncotarget       Date:  2017-03-07

5.  miR-300 rs12894467 polymorphism may be associated with susceptibility to primary lung cancer in the Chinese Han population.

Authors:  Zhiqiang Liu; Yong Lin; Shuling Kang; Qiuping Xu; Weimin Xiong; Lin Cai; Fei He
Journal:  Cancer Manag Res       Date:  2018-09-17       Impact factor: 3.989

6.  Association of Hsa-miR-23a rs3745453 variation with prostate cancer risk among Chinese Han population: A case-control study.

Authors:  Minhao Zhang; Yali Wang; Can Wang; Zonghao You; Shuqiu Chen; Qingfang Kong; Bin Xu; Chunhui Liu; Ming Chen
Journal:  Medicine (Baltimore)       Date:  2019-12       Impact factor: 1.817

7.  VEGF and bFGF gene polymorphisms in Polish patients with B-CLL.

Authors:  Tomasz Wróbel; Grzegorz Mazur; Justyna Dzietczenia; Katarzyna Gebura; Kazimierz Kuliczkowski; Katarzyna Bogunia-Kubik
Journal:  Med Oncol       Date:  2013-01-19       Impact factor: 3.064

8.  VEGF Polymorphisms Related to Higher Serum Levels of Protein Identify Patients with Hepatocellular Carcinoma.

Authors:  Maria Eduarda Lopes Baitello; Graciele Domitila Tenani; Rafael Fernandes Ferreira; Victor Nogueira; Marcela Augusta de Souza Pinhel; Rita de Cássia Martins Alves da Silva; Renato Ferreira da Silva; Patrícia da Silva Fucuta; Moacir Fernandes de Godoy; Dorotéia Rossi Silva Souza
Journal:  Can J Gastroenterol Hepatol       Date:  2016-08-31

9.  A randomised controlled trial of meloxicam, a Cox-2 inhibitor, to prevent hepatocellular carcinoma recurrence after initial curative treatment.

Authors:  Yuko Takami; Susumu Eguchi; Masaki Tateishi; Tomoki Ryu; Kazuhiro Mikagi; Yoshiyuki Wada; Hideki Saitsu
Journal:  Hepatol Int       Date:  2016-02-04       Impact factor: 6.047

Review 10.  Common Variants of the Prostaglandin-Endoperoxide Synthase 2 Gene and Hepatocellular Carcinoma Susceptibility.

Authors:  Hong-Guang Li; Fang-Feng Liu; Hua-Qiang Zhu; Xu Zhou; Jun Lu; Hong Chang; Jin-Hua Hu
Journal:  Medicine (Baltimore)       Date:  2015-09       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.